FT

AstraZeneca revises down efficacy rate for US Covid vaccine trial

New assessment lowers figure to 76% after criticism that earlier data was incomplete

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Back to top button